Design and preclinical testing of an anti-CD41 CAR T cell for the treatment of acute megakaryoblastic leukaemia
Funding Information: Adrian Bogdan Tigu and Catalin Constantinescu contributed equally to the current manuscript. Catalin Constantinescu is funded by an internal grant of the Iuliu Hatieganu University – School of Doctoral Studies. David Kegyes is funded by an internal grant of the Iuliu Hatieganu U...
Published in: | Journal of Cellular and Molecular Medicine |
---|---|
Main Authors: | , , , , , , , , , , , , , , , , , , , , , , |
Other Authors: | , |
Format: | Article in Journal/Newspaper |
Language: | English |
Published: |
2023
|
Subjects: | |
Online Access: | https://hdl.handle.net/20.500.11815/4463 https://doi.org/10.1111/jcmm.17810 |
Summary: | Funding Information: Adrian Bogdan Tigu and Catalin Constantinescu contributed equally to the current manuscript. Catalin Constantinescu is funded by an internal grant of the Iuliu Hatieganu University – School of Doctoral Studies. David Kegyes is funded by an internal grant of the Iuliu Hatieganu University – School of Medicine. Mareike Peters is funded by a national grant of the Romanian Society for Bone Marrow Transplantation. Ciprian Tomuleasa is also supported by a grant awarded by the Romanian National Ministry of Research, Innovation and Digitalization: PN‐III‐P4‐ID‐PCE‐2020‐1118 within PNCDI IV, Projects for Exploratory Medicine; Projects for Exploratory Medicine—PCE 225/2021; as well as a national grant awarded to Young Research Teams (PN‐III‐PI‐1.1‐TE‐2019‐0271 –‘Supporting a team of young researchers to create an independent research program based on the use of Sleeping Beauty protocol f or the development of CAR T Cells – SEATTLE’). Diana Gulei, Diana Cenariu, Adrian Bogdan Tigu, Jon Thor Bergthorsson and Victor Greiff are supported by an international collaborative grant of the European Economic Space between Romania and Iceland 2021–2023: ‘Cooperation strategy for knowledge transfer, internationalization and curricula innovation in the field of research education at the 3rd level of study –AURORA.’ Publisher Copyright: © 2023 The Authors. Journal of Cellular and Molecular Medicine published by Foundation for Cellular and Molecular Medicine and John Wiley & Sons Ltd. Acute megakaryoblastic leukaemia (AMkL) is a rare subtype of acute myeloid leukaemia (AML) representing 5% of all reported cases, and frequently diagnosed in children with Down syndrome. Patients diagnosed with AMkL have low overall survival and have poor outcome to treatment, thus novel therapies such as CAR T cell therapy could represent an alternative in treating AMkL. We investigated the effect of a new CAR T cell which targets CD41, a specific surface antigen for M7-AMkL, against an in vitro model for AMkL, DAMI Luc2 cell ... |
---|